Mechanisms of MPTP toxicity
- PMID: 9613716
Mechanisms of MPTP toxicity
Abstract
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) produces an experimental model of Parkinson's disease (PD). It replicates most of the clinical features of PD as well as the main biochemical and pathologic hallmarks of the disease. Although the MPTP model departs from PD in several aspects, it is thought that important insights into the neurodegenerative process of PD may be obtained by elucidating the molecular mechanism of MPTP. In this article, we summarize the different steps of the complex metabolic pathway of MPTP and show how they may be implicated in predisposing individuals to PD. We also outline findings pertinent to the mode of action of MPTP including overproduction of free radicals, implication of nitric oxide, nitration of tyrosine, impairment of mitochondrial respiration, and occurrence of apoptosis. All of these factors may participate in the cascade of deleterious events that ultimately lead to the death of dopaminergic neurons after MPTP administration. Because of the similarity between PD and the MPTP model, we are speculating that a similar scenario may underlie the neurodegenerative process in PD.
Similar articles
-
[Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity].Arch Neurobiol (Madr). 1992 Jul-Aug;55(4):175-82. Arch Neurobiol (Madr). 1992. PMID: 1417423 Review. Spanish.
-
[Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].Neurologia. 1991 Oct;6(8):287-94. Neurologia. 1991. PMID: 1790005 Review. Spanish.
-
CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.J Pharmacol Exp Ther. 1999 Feb;288(2):421-7. J Pharmacol Exp Ther. 1999. PMID: 9918541
-
A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery.Brain. 2007 Nov;130(Pt 11):2898-914. doi: 10.1093/brain/awm208. Epub 2007 Sep 13. Brain. 2007. PMID: 17855373
-
Effects of different schedules of MPTP administration on dopaminergic neurodegeneration in mice.Exp Neurol. 1997 Nov;148(1):288-92. doi: 10.1006/exnr.1997.6648. Exp Neurol. 1997. PMID: 9398471
Cited by
-
A survey from 2012 of evidence for the role of neuroinflammation in neurotoxin animal models of Parkinson's disease and potential molecular targets.Exp Neurol. 2014 Jun;256:126-32. doi: 10.1016/j.expneurol.2013.05.014. Epub 2013 May 28. Exp Neurol. 2014. PMID: 23726958 Free PMC article. Review.
-
Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse.PLoS One. 2015 Jun 26;10(6):e0131281. doi: 10.1371/journal.pone.0131281. eCollection 2015. PLoS One. 2015. PMID: 26114655 Free PMC article.
-
The Mitochondria-Regulated Immune Pathway Activated in the C. elegans Intestine Is Neuroprotective.Cell Rep. 2016 Aug 30;16(9):2399-414. doi: 10.1016/j.celrep.2016.07.077. Epub 2016 Aug 18. Cell Rep. 2016. PMID: 27545884 Free PMC article.
-
Vulnerability of mesostriatal dopaminergic neurons in Parkinson's disease.Front Neuroanat. 2010 Oct 20;4:140. doi: 10.3389/fnana.2010.00140. eCollection 2010. Front Neuroanat. 2010. PMID: 21079748 Free PMC article.
-
Curcumin pre-treatment may protect against mitochondrial damage in LRRK2-mutant Parkinson's disease and healthy control fibroblasts.Biochem Biophys Rep. 2021 Jun 16;27:101035. doi: 10.1016/j.bbrep.2021.101035. eCollection 2021 Sep. Biochem Biophys Rep. 2021. PMID: 34189277 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources